Assertio Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ASSERTIO, and when can generic versions of ASSERTIO drugs launch?
ASSERTIO has two approved drugs.
There are ten US patents protecting ASSERTIO drugs.
There are thirty-one patent family members on ASSERTIO drugs in twenty-three countries.
Summary for Assertio
| International Patents: | 31 |
| US Patents: | 10 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Assertio
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | AB | RX | Yes | Yes | 8,110,606 | See Plans and Pricing | See Plans and Pricing | |||
| Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | AB | RX | Yes | Yes | 8,623,920 | See Plans and Pricing | See Plans and Pricing | |||
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | 8,097,651 | See Plans and Pricing | Y | Y | See Plans and Pricing | |
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | 9,827,197 | See Plans and Pricing | Y | See Plans and Pricing | ||
| Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | AB | RX | Yes | Yes | 7,884,095 | See Plans and Pricing | See Plans and Pricing | |||
| Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | AB | RX | Yes | Yes | 7,939,518 | See Plans and Pricing | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Assertio
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | 6,974,595 | See Plans and Pricing |
| Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | 6,287,594 | See Plans and Pricing |
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | 7,482,377 | See Plans and Pricing |
| Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | 6,365,180 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ASSERTIO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2012-11-14 |
| ➤ Subscribe | Potassium Oral Solution (Sachet) | 50 mg | ➤ Subscribe | 2011-01-24 |
International Patents for Assertio Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2006257072 | See Plans and Pricing |
| Poland | 1890680 | See Plans and Pricing |
| World Intellectual Property Organization (WIPO) | 2006133954 | See Plans and Pricing |
| Guatemala | 200600261 | See Plans and Pricing |
| Ecuador | SP077989 | See Plans and Pricing |
| Canada | 2632375 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
